http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Recent progresses in marine microbial-derived antiviral natural products
Yun‑Fei Teng,Li Xu,Mei‑Yan Wei,Chang‑Yun Wang,Yu‑Cheng Gu,Chang‑Lun Shao 대한약학회 2020 Archives of Pharmacal Research Vol.43 No.12
Viruses have always been a class of pathogenicmicroorganisms that threaten the health and safety of humanlife worldwide. However, for a long time, the treatment ofviral infections has been slow to develop, and only a fewantiviral drugs have been using clinically. Compared withthese from terrestrial environments, marine-derived microorganismscan produce active substances with more novelstructures and unique functions. From 2015 to 2019, 89antiviral compounds of 8 structural classes have been isolatedfrom marine microorganisms, of which 35 exhibit anti-H1N1 activity. This review surveys systematically marinemicrobial-derived natural products with antiviral activityand illustrates the impact of these compounds on antiviraldrug discovery research.
Metabolites from the Fungus Cephalosporium sp. AL031
Yun-Mei Bi,Xu-Bin Bi,Fang A,Qian-Rong Zhao 대한약학회 2007 Archives of Pharmacal Research Vol.30 No.3
A new pyrone derivative, 7, 9-dihydroxy-10-methyl-2H, 4aH, 6H, 10bH-pyrano[5,6-c][2]benzopyran- 2,6-dione (1), was isolated from a culture broth of a strain of the fungus Cephalosporium sp. AL031, together with three known compounds, 3-acetyl-7-hydroxy-5-methoxyl-3Hisobenzofuran- 1-one (2), vermopyrone (3), and 5-methylmellein (4). Their structures were elucidated by spectroscopic analysis including MS and 2D-NMR. Compounds 2, 3, and 4 are reported for the first time from fermentation broth of this fungus through the present study.
A Fractal Velocity Model for Ellis Fluid Flow in Porous Media
Mei-Juan Yun 한국물리학회 2013 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.63 No.8
In this paper, we present a fractal model for the flow velocity for an Ellis fluid based on thefractal properties of porous media. The proposed expression quantitatively describes the relationbetween the properties of the Ellis fluid and the parameters of the micro structure of the porousmedium. The model prediction is compared with experimental data, and good agreement betweenthem is found. The analytical expression reveals the physical principles for the flow of Ellis fluidsand other non-Newtonian fluids in porous media.
( Mei Yun Ke ),( Jan Tack ),( Eamonn M M Quigley ),( Duo Wu Zou ),( Suck Chei Choi ),( Somchai Leelakusolvong ),( Andy Liu ),( Jin Yong Kim ) 대한소화기기능성질환·운동학회(구 대한소화관운동학회) 2014 Journal of Neurogastroenterology and Motility (JNM Vol.20 No.4
Background/Aims To compare the efficacy and safety of prucalopride, a novel selective high-affinity 5-hydroxytryptamine type 4 receptor agonist, versus placebo, in Asian and non-Asian women with chronic constipation (CC). Methods Data of patients with CC, receiving once-daily prucalopride 2-mg or placebo for 12-weeks, were pooled from 4 double-blind, randomized, phase-III trials (NCT00488137, NCT00483886, NCT00485940 and NCT01116206). The efficacy endpoints were: average of ≥ 3 spontaneous complete bowel movements (SCBMs)/week; average increases of ≥ 1 SCBMs/week; and change from baseline in each CC-associated symptom scores (bloating, abdominal pain, hard stool and straining).Results Overall, 1,596 women (Asian [26.6%], non-Asian [73.4%]) were included in this analysis. Significantly more patients in the prucalopride group versus placebo experienced an average of ≥ 3 SCBMs/week in Asian (34% vs. 11%, P < 0.001) and non-Asian (24.6% vs. 10.6%, P < 0.001) subgroups. The number of patients reporting an increase of ≥ 1 SCBMs/week from baseline was significantly higher in the prucalopride group versus placebo among both Asian (57.4% vs. 28.3%, P < 0.001) and non-Asian (45.3% vs. 24.0%, P < 0.001) subgroups. The difference between the subgroups was not statistically significant. Prucalopride significantly reduced the symptom scores for bloating, hard stool, and straining in both subgroups. Conclusions Prucalopride 2-mg once-daily treatment over 12-weeks was more efficacious than placebo in promoting SCBMs and improvement of CC-associated symptoms in Asian and non-Asian women, and was found to be safe and well-tolerated. There were numeric differences between Asian and non-Asian patients on efficacy and treatment emergent adverse events, which may be partially due to the overlap with functional gastrointestinal disorders in non-Asian patients.(J Neurogastroenterol Motil 2014;20:458-468)
Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome
Xi-Mei Zhang,Yun-Bo Zhang,Mei-Hua Chi 연세대학교의과대학 2016 Yonsei medical journal Vol.57 No.3
Purpose: Clinical trials have studied the use of soy protein for treating type 2 diabetes (T2D) and metabolic syndrome (MS). The purpose of this study was to outline evidence on the effects of soy protein supplementation on clinical indices in T2D and MS subjects by performing a meta-analysis of randomized controlled trials (RCTs). Materials and Methods: We searched PubMed, EMBASE, and Cochrane databases up to March 2015 for RCTs. Pooled estimates and 95% confidence intervals (CIs) were calculated by the fixed-and-random-effects model. A total of eleven studies with eleven clinical variables met the inclusion criteria. Results: The meta-analysis showed that fasting plasma glucose (FPG) [weighted mean difference (WMD), -0.207; 95% CI, -0.374 to -0.040; p=0.015], fasting serum insulin (FSI) (WMD, -0.292; 95% CI, -0.496 to -0.088; p=0.005), homeostasis model of assessmentfor insulin resistance index (HOMA-IR) (WMD, -0.346; 95% CI, -0.570 to -0.123; p=0.002), diastolic blood pressure (DBP) (WMD, -0.230; 95% CI, -0.441 to -0.019; p=0.033), low-density lipoprotein cholesterol (LDL-C) (WMD, -0.304; 95% CI, -0.461 to -0.148; p=0.000), total cholesterol (TC) (WMD, -0.386; 95% CI, -0.548 to -0.225; p=0.000), and C-reactive protein (CRP) (WMD, -0.510; 95% CI, -0.722 to -0.299; p=0.000) are significant reduced with soy protein supplementation, compared with a placebo control group, in T2D and MS patients. Furthermore, soy protein supplementation for longer duration (≥6 mo) significantly reducedFPG, LDL-C, and CRP, while that for a shorter duration (<6 mo) significantly reduced FSI and HOMA-IR. Conclusion: Soy protein supplementation could be beneficial for FPG, FSI, HOMA-IR, DBP, LDL-C, TC, and CRP control in plasma.
리튬-황 전지용 프리스탠딩 플렉서블 S/CNT/NiO 전극의 제조 및 전기화학적 특성
신윤정 ( Yun Jung Shin ),이원열 ( Won Yeol Lee ),김태윤 ( Tae Yun Kim ),문승근 ( Seung-guen Moon ),김은미 ( En Mei Jin ),정상문 ( Sang Mun Jeong ) 한국화학공학회 2022 Korean Chemical Engineering Research(HWAHAK KONGHA Vol.60 No.2
수열합성을 통해 합성한 다공성 NiO는 리튬 폴리설파이드의 용출을 억제하기 위하여 리튬-황 전지의 전극에 사용되었다. 리튬-황 전지의 전극은 경제적이고 간단한 진공 여과 방법을 이용하여 집전체와 바인더가 없는 프리스탠딩 플렉서블 전극으로 제작되었다. 다공성 NiO를 첨가한 S/CNT/NiO 전극은 순수 S/CNT 전극에 비해 125 mA h g<sup>-1</sup> 증가한 877 mA h g<sup>-1</sup> (0.2 C)의 초기 방전용량과 200 사이클 후 84% (S/CNT: 66%)의 우수한 용량 유지율을 나타내었다. 이는 방전 과정 중에서 NiO와 리튬 폴리설파이드의 강한 화학적 결합에 의하여 리튬 폴리설파이드의 전해질로 용출되는 것을 억제하여 나타난 결과이다. 또한 S/CNT/NiO 전극의 유연성 테스트를 위해 1.6 × 4 ㎠의 파우치셀로 제작하여 폴딩한 상태와 하지 않은 상태에서 모두 620 mA h g<sup>-1</sup>의 안정적인 사이클 특성을 나타내었다. Porous NiO synthesized via hydrothermal synthesis was used in the electrodes of lithium-sulfur batteries to inhibit the elution of lithium polysulfide. The electrode of the lithium-sulfur battery was manufactured as a freestanding flexible electrode using an economical and simple vacuum filtration method without a current collector and a binder. The porous NiO-added S/CNT/NiO electrode exhibited a high initial discharge capacity of 877 mA h g<sup>-1</sup> (0.2 C), which was 125 mA h g<sup>-1</sup> higher than that of S/CNT, and also showed excellent retention of 84% (S/CNT: 66%). This is the result of suppressing the dissolution of lithium polysulfide into the electrolyte by the strong chemical bond between NiO and lithium polysulfide during the charging and discharging process. In addition, for the flexibility test of the S/CNT/NiO electrode, the 1.6 × 4 ㎠ pouch cell was prepared and exhibited stable cycle characteristics of 620 mA h g<sup>-1</sup> in both the unfolded and folded state.
Tian-Mei Si,Yun-shu Zhang,Liang Shu,Ke-Qing Li,Xie-He Liu,Qi-Yi Mei,Gao-Hua Wang,Pei-Shen Bai,Li-Ping Ji,Xian-Sheng Cheng,Cui Ma,Jian-Guo Shi,Hong-Yan Zhang,Hong Ma,Xin Yu 대한정신약물학회 2012 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.10 No.2
Objective: Clozapine is one of the most commonly used antipsychotic drugs in China. To date, few studies have investigated the patterns the prescription of clozapine nationwide. The present study examined these patterns in China in 2006 and identified the demographic and clinical characteristics associated with the use of clozapine. Methods: Using a standardized protocol and data collection procedure, we surveyed 5,898 patients with schizophrenia in 10provinces with differing levels of economic development. Results: Overall, clozapine had been prescribed for 31.9% (n=1,883) of the patients; however we found considerable variation among the 10 provinces. The frequency of clozapine use was highest in Sichuan (39.3%) and lowest in Beijing (17.3%). The mean daily dose of clozapine was 210.36±128.72 mg/day, and 25.1% of the patients were treated with clozapine in combination with other antipsychotics. Compared with the group not receiving clozapine, clozapine-user had been treated for longer durations and had experienced a greater number of relapses and hospitalizations. Furthermore, those in the clozapine-user had lower family incomes, were less able to seek psychiatric services, and more likely to be male and have a positive family history of schizophrenia. A multiple logistic regression analysis revealed that age, sex, professional help-seeking behaviors, duration of illness, economic status, educational level, and clinical manifestations were associated with the use of clozapine. Conclusion: Clozapine use is common in China. However, use of the antipsychotic varies among provinces, and demographic and clinical factors play important roles in the prescription of clozapine.